BiotechTube
Home/Pipeline/MW-504

MW-504

Obesity, Chronic Kidney Disease

PreclinicalActive

Key Facts

Indication
Obesity, Chronic Kidney Disease
Phase
Preclinical
Status
Active
Company
Mwyngil Therapeutics

About Mwyngil Therapeutics

AI‑powered biotech creating oral NLRP3 and GPR75 small‑molecule drugs for obesity and CKD.

View full company profile

Therapeutic Areas

ObesityChronic Kidney DiseaseInflammatory DiseasesNeurodegenerationCardiovascular Disease

Other Obesity, Chronic Kidney Disease Drugs

DrugCompanyPhase
MW-401Mwyngil TherapeuticsPreclinical